about us

  GNOMX Corp. (“GNOMX” or the “Company”), based in New York City, was founded in October 2022 to commercialize host response epigenetic diagnostics based on research funded by a $46 million Defense Advanced Research Projects Agency (DARPA) ECHO program contract to an academic consortium including the Icahn School of Medicine at Mount Sinai (“ISMMS”), lead, Yale University School of Medicine, Princeton University, and University of Pittsburgh School of Medicine.

The DARPA-sponsored research program developed patent-pending, beyond state-of-art methods and proof-of-principle epigenetic tests that rapidly diagnose, determine time of exposure, and monitor long-term effects of infections and other exposures. GNOMX believes that it can transform infectious disease assessment, diagnosis and treatment.

GNOMX's next-generation platform provides high-specificity, low cross-reactivity, and compatibility with rapid diagnostic assays that are highly advantageous compared to any existing diagnostic or prognostic technology (e.g., enabling diagnostics long after original pathogen has vanished). Our platform can rapidly develop diagnostic and prognostic tests for emerging pathogens and their sequelae.